Published in:
01-11-2016 | Original Article
Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study
Authors:
C. Orvain, D. Luque Paz, I. Dobo, L. Cottin, G. Le Calvez, A. Chauveau, M. Mercier, J. Farhi, F. Boyer, J. C. Ianotto, B. Guibourg, M. C. Rousselet, M. Zandecki, N. Ifrah, M. Hunault-Berger, V. Ugo, F. Genevieve
Published in:
Annals of Hematology
|
Issue 11/2016
Login to get access
Abstract
A high number of circulating CD34+ cells has been advocated to distinguish primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms. We re-evaluated the diagnostic interest of measuring circulating CD34+ cells in 26 healthy volunteers and 256 consecutive patients at diagnosis for whom a myeloproliferative neoplasm was suspected. The ROC curve analysis showed that a number of CD34+ <10/μl excludes the diagnosis of primary myelofibrosis with a sensitivity of 97 % and a specificity of 90 % (area under the curve: 0.93 [0.89–0.98]; p < 0.001). Patients with PMF harboring a CALR mutation had more circulating CD34+ cells than patients with either a JAK 2 or MPL mutation (p = 0.02 and p < 0.01, respectively). These results suggest that this fast, simple, non-invasive, and standardized test is of particular interest to exclude the diagnosis of primary myelofibrosis.